Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

Background Overactivation of human epidermal growth factor receptor 3 (HER3) triggers multiple intracellular pathways resulting in tumor cell survival. This Phase 1 study assessed the safety, efficacy, and pharmacokinetics (PK) of seribantumab, a fully human anti-HER3 monoclonal antibody. Methods Ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Denlinger, Crystal S., Keedy, Vicki L., Moyo, Victor, MacBeath, Gavin, Shapiro, Geoffrey I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541959/
https://www.ncbi.nlm.nih.gov/pubmed/34250553
http://dx.doi.org/10.1007/s10637-021-01145-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541959/
https://www.ncbi.nlm.nih.gov/pubmed/34250553
http://dx.doi.org/10.1007/s10637-021-01145-y

Ejemplares similares